Bausch Health up premarket as turnaround continues, guidance raised

Bausch Health Companies (NYSE:BHC) Q3 results:

Revenues: $2,209M (+3.4%); B + L: $1,175M (+2.4%); Salix: $551M (+19.8%); Ortho Dermatologics: $147M (-16.5%).

Xifaxan sales up 24%.

Ne loss: ($49M) (+86.0%); non-GAAP net income: $425M (+5.5%); loss/share: ($0.14) (+86.0%); non-GAAP EBITDA: $942M (+2.8%).

Cash flow ops: $515M.

2019 guidance: Revenues: $8.475B – 8.625B from $8.400B – 8.600B; non-GAAP EBITDA: $3.500B – 3.600B from $3.425B – 3.575B.

Shares up 3% premarket on modest volume.

https://seekingalpha.com/news/3513504-bausch-health-3-percent-premarket-turnaround-continues-guidance-raised